| 1 |
33881209 | A phase 1 study of prexasertib (LY2606368), a CHK1/2 inhibitor, in pediatric patients with recurrent or refractory solid tumors, including CNS tumors: A report from the Children's Oncology Group Pediatric Early Phase Clinical Trials Network (ADVL1515). | 2021 Sep |
1 |
| 2 |
31512029 | Prexasertib, a checkpoint kinase inhibitor: from preclinical data to clinical development. | 2020 Jan |
2 |
| 3 |
27438145 | Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia. | 2016 Aug 16 |
1 |